- 2026年会有汉坦病毒疫苗吗？2¢2%
No hantavirus vaccine is positioned for approval or broad availability by the end of 2026. All active candidates remain in preclinical or very early clinical stages, with no advanced human efficacy trials underway. Recent mRNA platforms, including single-dose candidates tested in hamsters at UTMB and work by Moderna with Korea University, have shown strong protection in rodent models against strains like Andes virus, yet these have not entered Phase 1 human testing. Older DNA vaccine efforts have completed limited Phase 1 safety studies but lack large-scale efficacy data or regulatory advancement. The 2026 cruise-ship outbreak has heightened awareness and prompted some funding discussions, yet development timelines for new vaccines—especially against regionally variable hantaviruses—typically span multiple years absent an extraordinary acceleration program. Realistic shifts before year-end would require unprecedented regulatory fast-tracking or emergency authorization based on preliminary data, scenarios viewed as improbable given current pipelines and resource constraints.
规则
如果任何用于人体并能使人对汉坦病毒产生免疫的疫苗（包括汉坦病毒肺综合征（HPS）或肾综合征出血热（HFRS）疫苗）在市场创建日至 2026年12月31日, 23:59 ET 之间获得美国食品药品管理局的完全批准，则该市场将判定为“是”。否则，本市场将以“否”结算。 本市场的主要判定依据将是美国食品药品管理局（FDA）的官方信息，包括其已批准疫苗名单（https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states）；不过，也可参考可信报道形成的共识。
机器翻译。如有争议，以原文为准。